158 related articles for article (PubMed ID: 9823960)
1. CD44 isoforms distinguish between bone marrow plasma cells from normal individuals and patients with multiple myeloma at different stages of disease.
van Driel M; Günthert U; Stauder R; Joling P; Lokhorst HM; Bloem AC
Leukemia; 1998 Nov; 12(11):1821-8. PubMed ID: 9823960
[TBL] [Abstract][Full Text] [Related]
2. CD44 variant isoforms are involved in plasma cell adhesion to bone marrow stromal cells.
Van Driel M; Günthert U; van Kessel AC; Joling P; Stauder R; Lokhorst HM; Bloem AC
Leukemia; 2002 Jan; 16(1):135-43. PubMed ID: 11840273
[TBL] [Abstract][Full Text] [Related]
3. Different CD44 splicing patterns define prognostic subgroups in multiple myeloma.
Stauder R; Van Driel M; Schwärzler C; Thaler J; Lokhorst HM; Kreuser ED; Bloem AC; Günthert U; Eisterer W
Blood; 1996 Oct; 88(8):3101-8. PubMed ID: 8874209
[TBL] [Abstract][Full Text] [Related]
4. Expression of CD44 variant exons in acute myeloid leukemia is more common and more complex than that observed in normal blood, bone marrow or CD34+ cells.
Bendall LJ; Bradstock KF; Gottlieb DJ
Leukemia; 2000 Jul; 14(7):1239-46. PubMed ID: 10914548
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD44 isoforms on isolated bone marrow plasma cells and peripheral CD19+ B cells of patients with multiple myeloma and healthy individuals.
Schuster-Kolbe J; Ludwig H; Adolf GR; Heider KH
Leuk Lymphoma; 1999 Jun; 34(1-2):95-103. PubMed ID: 10350336
[TBL] [Abstract][Full Text] [Related]
6. CD44 isoforms are differentially regulated in plasma cell dyscrasias and CD44v9 represents a new independent prognostic parameter in multiple myeloma.
Eisterer W; Bechter O; Hilbe W; van Driel M; Lokhorst HM; Thaler J; Bloem AC; Günthert U; Stauder R
Leuk Res; 2001 Dec; 25(12):1051-7. PubMed ID: 11684276
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD44 variant isoforms in peripheral blood leukocytes in malignant lymphoma and leukemia: inverse correlation between expression and tumor progression.
Khaldoyanidi S; Achtnich M; Hehlmann R; Zöller M
Leuk Res; 1996 Oct; 20(10):839-51. PubMed ID: 8960109
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma.
Dahl IM; Rasmussen T; Kauric G; Husebekk A
Br J Haematol; 2002 Feb; 116(2):273-7. PubMed ID: 11841427
[TBL] [Abstract][Full Text] [Related]
9. Differential expressions of CD44 variants in tumors affecting the central nervous system.
Resnick DK; Resnick NM; Welch WC; Cooper DL
Mol Diagn; 1999 Sep; 4(3):219-32. PubMed ID: 10553022
[TBL] [Abstract][Full Text] [Related]
10. Kunitz-type protease inhibitor bikunin disrupts phorbol ester-induced oligomerization of CD44 variant isoforms containing epitope v9 and subsequently suppresses expression of urokinase-type plasminogen activator in human chondrosarcoma cells.
Suzuki M; Kobayashi H; Fujie M; Nishida T; Takigawa M; Kanayama N; Terao T
J Biol Chem; 2002 Mar; 277(10):8022-32. PubMed ID: 11777908
[TBL] [Abstract][Full Text] [Related]
11. Isoform switch of CD44 induces different chemotactic and tumorigenic ability in gallbladder cancer.
Miwa T; Nagata T; Kojima H; Sekine S; Okumura T
Int J Oncol; 2017 Sep; 51(3):771-780. PubMed ID: 28677740
[TBL] [Abstract][Full Text] [Related]
12. Frequent expression of the high molecular, 673-bp CD44v3,v8-10 variant in colorectal adenomas and carcinomas.
Kopp R; Fichter M; Schalhorn G; Danescu J; Classen S
Int J Mol Med; 2009 Nov; 24(5):677-83. PubMed ID: 19787202
[TBL] [Abstract][Full Text] [Related]
13. CD44 variant exons in leukemia and lymphoma.
Akisik E; Bavbek S; Dalay N
Pathol Oncol Res; 2002; 8(1):36-40. PubMed ID: 11994761
[TBL] [Abstract][Full Text] [Related]
14. Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation.
Khan SA; Cook AC; Kappil M; Günthert U; Chambers AF; Tuck AB; Denhardt DT
Clin Exp Metastasis; 2005; 22(8):663-73. PubMed ID: 16691370
[TBL] [Abstract][Full Text] [Related]
15. Expression of CD44 splice variants in human primary brain tumors.
Kaaijk P; Troost D; Morsink F; Keehnen RM; Leenstra S; Bosch DA; Pals ST
J Neurooncol; 1995 Dec; 26(3):185-90. PubMed ID: 8750184
[TBL] [Abstract][Full Text] [Related]
16. CD44 expression in soft tissue sarcomas.
Kahara N; Ozaki T; Doi T; Nishida K; Kawai A; Shibahara M; Inoue H
Virchows Arch; 2000 Jun; 436(6):574-8. PubMed ID: 10917171
[TBL] [Abstract][Full Text] [Related]
17. Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy.
Kallakury BV; Yang F; Figge J; Smith KE; Kausik SJ; Tacy NJ; Fisher HA; Kaufman R; Figge H; Ross JS
Cancer; 1996 Oct; 78(7):1461-9. PubMed ID: 8839552
[TBL] [Abstract][Full Text] [Related]
18. Distinct expression patterns of CD44 isoforms during human lung development and in pulmonary fibrosis.
Kasper M; Günthert U; Dall P; Kayser K; Schuh D; Haroske G; Müller M
Am J Respir Cell Mol Biol; 1995 Dec; 13(6):648-56. PubMed ID: 7576702
[TBL] [Abstract][Full Text] [Related]
19. Expression of CD44 splice variant v10 in Hodgkin's disease is associated with aggressive behaviour and high risk of relapse.
Beham-Schmid C; Heider KH; Hoefler G; Zatloukal K
J Pathol; 1998 Dec; 186(4):383-9. PubMed ID: 10209487
[TBL] [Abstract][Full Text] [Related]
20. Expression of epidermal growth factor receptor and CD44 splicing variants sharing exons 6 and 9 on gastric and esophageal carcinomas: a two-color flow-cytometric analysis.
Koyama S; Maruyama T; Adachi S
J Cancer Res Clin Oncol; 1999; 125(1):47-54. PubMed ID: 10037277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
